Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report)'s stock price traded down 3.6% on Thursday . The company traded as low as $6.00 and last traded at $6.10. 32,917 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 87,455 shares. The stock had previously closed at $6.33.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Morgan Stanley assumed coverage on shares of Kalaris Therapeutics in a report on Thursday, April 16th. They issued an "overweight" rating and a $14.00 price target on the stock. Finally, Wall Street Zen raised shares of Kalaris Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, March 15th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $14.00.
View Our Latest Research Report on Kalaris Therapeutics
Kalaris Therapeutics Stock Performance
The stock has a 50 day moving average of $7.80 and a 200-day moving average of $7.49. The firm has a market capitalization of $139.87 million, a P/E ratio of -1.45 and a beta of 0.18.
Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.12. As a group, sell-side analysts expect that Kalaris Therapeutics Inc. will post -2.18 EPS for the current year.
Institutional Investors Weigh In On Kalaris Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KLRS. RTW Investments LP bought a new stake in Kalaris Therapeutics in the 4th quarter valued at about $10,972,000. Paradigm Biocapital Advisors LP bought a new stake in Kalaris Therapeutics in the 4th quarter valued at about $5,908,000. Alyeska Investment Group L.P. bought a new stake in Kalaris Therapeutics in the 4th quarter valued at about $3,402,000. Ikarian Capital LLC bought a new stake in Kalaris Therapeutics in the 4th quarter valued at about $3,038,000. Finally, Woodline Partners LP bought a new stake in Kalaris Therapeutics in the 3rd quarter valued at about $1,394,000. 66.05% of the stock is currently owned by institutional investors.
Kalaris Therapeutics Company Profile
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kalaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kalaris Therapeutics wasn't on the list.
While Kalaris Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
